Format

Send to

Choose Destination
See comment in PubMed Commons below
JAMA. 2013 Dec 18;310(23):2510-22. doi: 10.1001/jama.2013.282183.

Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.

Collaborators (183)

Feres F, Leon M, Bhatt DL, King S, Botelho R, Costa RA, Negoita M, Mehran R, Collier T, Timerman A, Rassi A Jr, Berwanger O, Tanajura LF, Almeida B, Alves C, Atra M, Centemero M, Braga S, Chaves A, Moreira A, Siqueira D, Abizaid AS, de Castro J, Davanzo L, Oyama L, Faria L, Silva K, Coelho F, Navarro P, Laporte R, Yazawa P, Scalabrini C, Costa RA, Lima M, di Monaco R, Rodrigues F, Ribeiro N, Ferreira A, Homsi J, Zaninelo K, Feres F, Abizaid A, Costa RA, Costa J Jr, Maldonado G, Siqueira D, Staico R, Chamié D, Tanajura LF, Centemero M, Chaves A, Abizaid AS, Viana R, Paiva P, Yagihara M, Sousa A, Sousa J, de Paula JT, Silva A, Biancardi C, Mangione JA, Mauro MF, Carnieto N, Cristovão S, Olah I, Botelho R, Rezende A, Cunha S, Mendonça E, Salvadori D Jr, Tiossi R, Ribeiro V Jr, Quiñones J, Miranda J, Faldin P, Osugue R, Goulart R, Zemuner M, Gusmão M, Saraiva V, Castello H Jr, Cantarelli M, Ribeiro EP, Baradel S, Nicolela EL Jr, Pagani M, Perin M, Janella B, Kitze S, Devito F, Menezes M, Marin-Neto J, Novaes G, Tonani M, Silva A, Meireles GX, Marchiori G, Galon M, Kreimer S, Watanabe E, Labrunie A, Tebet M, Andrade P, Barbosa R, Andrade M, Araújo N, Sanchez A, Trindade I, Boaventura R, Berti S, Verzola A, Furquim E, Teixeirense P, Gubolino L, Toledo J, Teixeirense P, Gubolino L, Toledo J, Bragalha A, Padilha S, Barbeiro M, Kormann A, Ultramari F, Marchi A, Padilha R, Cardoso G, Sarmento-Leite R, Bernardi G, Sousa L, Rodrigues J, Lima Filho A, Brito AL, Martins H, Morais G, Lima J, Lopes M, Barros M, Queiroz S, Nunes G, Roso D, Colnaghi I, Motta P, Branco C, Guimarães H, Araújo M, São Thiago LE, Dullius M, Conceição R, Caramori P, Gomes V, Lasevitch R, Pellegrini D, Sinnot L, Silveira C, Ledur P, Zago A, Matte B, Ruschel K, Pereira L, Machado A, Silva A, Saad JA, Marinho M, Falchetto EB, de Araújo EC, Croner SR, Zimmermann A, Sare L, Mandil A, Rodrigues S, Garcia C, dos Santos M, Esteves D, Souza AP, Brar S, Bousquette L, Gilbert C, Fagioli HG, Lazarus G, Rodrigues J, Porto O, Sardi C, Venuto E.

Author information

1
Instituto Dante Pazzanese de Cardiologia, São Paulo, São Paulo, Brazil.
2
New York Presbyterian Medical Center, Columbia University Medical Center, and the Cardiovascular Research Foundation, New York, New York.
3
University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
4
Instituto do Coração do Triângulo Mineiro, Uberlândia, Minas Gerais, Brazil.
5
Saint Joseph's Medical Group, Atlanta, Georgia.
6
Medtronic CardioVascular, Santa Rosa, California.
7
Unicor de Linhares, Linhares, Espírito Santo, Brazil.
8
Hospital Beneficência Portuguesa de São Paulo, São Paulo, São Paulo, Brazil.
9
Hospital Público Estadual de São Paulo, São Paulo, São Paulo, Brazil.
10
Hospital Bandeirantes, São Paulo, São Paulo, Brazil.
11
Emcor Emergências do Coração, Piracicaba, São Paulo, Brazil.
12
Hospital Santa Marcelina, São Paulo, Brazil.
13
Hospital Padre Albino-FIPA, Catanduva, São Paulo, Brazil.
14
Santa Casa de Misericórdia de Marilia, Marilia, São Paulo, Brazil.
15
Hospital Agamenon Magalhães, Recife, Pernambuco, Brazil.
16
Cardiovascular Research Center, São Paulo, São Paulo, Brazil.
17
VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

Abstract

IMPORTANCE:

The current recommendation is for at least 12 months of dual antiplatelet therapy after implantation of a drug-eluting stent. However, the optimal duration of dual antiplatelet therapy with specific types of drug-eluting stents remains unknown.

OBJECTIVE:

To assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) with zotarolimus-eluting stents.

DESIGN, SETTING, AND PATIENTS:

The OPTIMIZE trial was an open-label, active-controlled, 1:1 randomized noninferiority study including 3119 patients in 33 sites in Brazil between April 2010 and March 2012. Clinical follow-up was performed at 1, 3, 6, and 12 months. Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents.

INTERVENTIONS:

After PCI with zotarolimus-eluting stents, patients were prescribed aspirin (100-200 mg daily) and clopidogrel (75 mg daily) for 3 months (n = 1563) or 12 months (n = 1556), unless contraindicated because of occurrence of an end point.

MAIN OUTCOMES AND MEASURES:

The primary end point was net adverse clinical and cerebral events (NACCE; a composite of all-cause death, myocardial infarction [MI], stroke, or major bleeding); the expected event rate at 1 year was 9%, with a noninferiority margin of 2.7%. Secondary end points were major adverse cardiac events (MACE; a composite of all-cause death, MI, emergent coronary artery bypass graft surgery, or target lesion revascularization) and Academic Research Consortium definite or probable stent thrombosis.

RESULTS:

NACCE occurred in 93 patients receiving short-term and 90 patients receiving long-term therapy (6.0% vs 5.8%, respectively; risk difference, 0.17 [95% CI, -1.52 to 1.86]; P = .002 for noninferiority). Kaplan-Meier estimates demonstrated MACE rates at 1 year of 8.3% (128) in the short-term group and 7.4% (114) in the long-term group (HR, 1.12 [95% CI, 0.87-1.45]). Between 91 and 360 days, no statistically significant association was observed for NACCE (39 [2.6%] vs 38 [2.6%] for the short- and long-term groups, respectively; HR, 1.03 [95% CI, 0.66-1.60]), MACE (78 [5.3%] vs 64 [4.3%]; HR, 1.22 [95% CI, 0.88-1.70]), or stent thrombosis (4 [0.3%] vs 1 [0.1%]; HR, 3.97 [95% CI, 0.44-35.49]).

CONCLUSIONS AND RELEVANCE:

In patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without significantly increasing the risk of stent thrombosis.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT01113372.

PMID:
24177257
DOI:
10.1001/jama.2013.282183
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center